Bullish
Anika Therapeutics Posts Strong Q1 2026 Revenue Growth
Anika Therapeutics reported a robust Q1 2026 with revenue up 13% to $29.6 million and adjusted EBITDA climbing to $4.3 million, driven by strong growt...
ANIK
--
--
--
--
Price Chart (30 Days)
Ad Space
Analyst Sentiment
Bullish (1)
Neutral (0)
Bearish (0)
Latest ANIK News
Bullish
Research ANIK on:
Ad Space